Skip to main content
Top
Published in: Pediatric Nephrology 2/2016

Open Access 01-02-2016 | Review

Primary hypertension is a disease of premature vascular aging associated with neuro-immuno-metabolic abnormalities

Authors: Mieczysław Litwin, Janusz Feber, Anna Niemirska, Jacek Michałkiewicz

Published in: Pediatric Nephrology | Issue 2/2016

Login to get access

Abstract

There is an increasing amount of data indicating that primary hypertension (PH) is not only a hemodynamic phenomenon but also a complex syndrome involving abnormal fat tissue distribution, over-activity of the sympathetic nervous system (SNS), metabolic abnormalities, and activation of the immune system. In children, PH usually presents with a typical phenotype of disturbed body composition, accelerated biological maturity, and subtle immunological and metabolic abnormalities. This stage of the disease is potentially reversible. However, long-lasting over-activity of the SNS and immuno-metabolic alterations usually lead to an irreversible stage of cardiovascular disease. We describe an intermediate phenotype of children with PH, showing that PH is associated with accelerated development, i.e., early premature aging of the immune, metabolic, and vascular systems. The associations and determinants of hypertensive organ damage, the principles of treatment, and the possibility of rejuvenation of the cardiovascular system are discussed.
Literature
2.
go back to reference Harrison DG (2013) The mosaic theory revisited: common molecular mechanisms coordinating diverse organ and cellular events in hypertension. J Am Soc Hypertens 7:68–74PubMedPubMedCentralCrossRef Harrison DG (2013) The mosaic theory revisited: common molecular mechanisms coordinating diverse organ and cellular events in hypertension. J Am Soc Hypertens 7:68–74PubMedPubMedCentralCrossRef
3.
go back to reference Paradis G, Lambert M, O’Loughlin J, Lavallée C, Aubin J, Delvin E, Lévy E, Hanley JA (2004) Blood pressure and adiposity in children and adolescents. Circulation 110:1832–1838PubMedCrossRef Paradis G, Lambert M, O’Loughlin J, Lavallée C, Aubin J, Delvin E, Lévy E, Hanley JA (2004) Blood pressure and adiposity in children and adolescents. Circulation 110:1832–1838PubMedCrossRef
4.
go back to reference Sorof J, Daniels S (2002) Obesity hypertension in children: a problem of epidemic proportions. Hypertension 40:441–447PubMedCrossRef Sorof J, Daniels S (2002) Obesity hypertension in children: a problem of epidemic proportions. Hypertension 40:441–447PubMedCrossRef
5.
go back to reference Flynn JT, Alderman MH (2005) Characteristics of children with primary hypertension seen at a referral centre. Pediatr Nephrol 20:961–966PubMedCrossRef Flynn JT, Alderman MH (2005) Characteristics of children with primary hypertension seen at a referral centre. Pediatr Nephrol 20:961–966PubMedCrossRef
6.
go back to reference Litwin M, Trelewicz J, Wawer Z, Antoniewicz J, Wierzbicka A, Rajszys P, Grenda R (2004) Intima-media thickness and arterial elasticity in hypertensive children: controlled study. Pediatr Nephrol 19:767–774PubMedCrossRef Litwin M, Trelewicz J, Wawer Z, Antoniewicz J, Wierzbicka A, Rajszys P, Grenda R (2004) Intima-media thickness and arterial elasticity in hypertensive children: controlled study. Pediatr Nephrol 19:767–774PubMedCrossRef
7.
go back to reference Srinivasan SR, Myers L, Berenson GS (2006) Changes in metabolic syndrome variables since childhood in pre-hypertensive and hypertensive subjects: the Bogalusa Heart Study. Hypertension 48:33–39PubMedCrossRef Srinivasan SR, Myers L, Berenson GS (2006) Changes in metabolic syndrome variables since childhood in pre-hypertensive and hypertensive subjects: the Bogalusa Heart Study. Hypertension 48:33–39PubMedCrossRef
8.
go back to reference Sinaiko A, Steinberger J, Moran A, Hong C, Prineas R, Jacobs D (2006) Influence of insulin resistance and body mass index at Age 13 on systolic blood pressure, triglycerides, and high-density lipoprotein cholesterol at Age 19. Hypertension 48:730–736PubMedCrossRef Sinaiko A, Steinberger J, Moran A, Hong C, Prineas R, Jacobs D (2006) Influence of insulin resistance and body mass index at Age 13 on systolic blood pressure, triglycerides, and high-density lipoprotein cholesterol at Age 19. Hypertension 48:730–736PubMedCrossRef
9.
go back to reference Pludowski P, Litwin M, Sladowska J, Antoniewicz J, Niemirska A, Wierzbicka A, Lorenc RS (2008) Bone mass and body composition in children and adolescents with primary hypertension: preliminary data. Hypertension 51:77–83PubMedCrossRef Pludowski P, Litwin M, Sladowska J, Antoniewicz J, Niemirska A, Wierzbicka A, Lorenc RS (2008) Bone mass and body composition in children and adolescents with primary hypertension: preliminary data. Hypertension 51:77–83PubMedCrossRef
10.
go back to reference Litwin M, Sladowska J, Antoniewicz J, Niemirska A, Wierzbicka A, Daszkowska J, Wawer ZT, Janas R, Grenda R (2007) Metabolic abnormalities, insulin resistance, and metabolic syndrome in children with primary hypertension. Am J Hypertens 20:875–882PubMedCrossRef Litwin M, Sladowska J, Antoniewicz J, Niemirska A, Wierzbicka A, Daszkowska J, Wawer ZT, Janas R, Grenda R (2007) Metabolic abnormalities, insulin resistance, and metabolic syndrome in children with primary hypertension. Am J Hypertens 20:875–882PubMedCrossRef
13.
go back to reference Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300:924–932PubMedPubMedCentralCrossRef Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300:924–932PubMedPubMedCentralCrossRef
14.
go back to reference Redón J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, Sáez GT (2003) Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 41:1096–1101PubMedCrossRef Redón J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, Sáez GT (2003) Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 41:1096–1101PubMedCrossRef
15.
go back to reference Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ (1997) Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 15:901–909PubMedCrossRef Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ (1997) Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 15:901–909PubMedCrossRef
16.
go back to reference Ostrow V, Wu S, Aguilar A, Bonner R Jr, Suarez E, De Luca F (2011) Association between oxidative stress and masked hypertension in a multi-ethnic population of obese children and adolescents. J Pediatr 158:628–633PubMedCrossRef Ostrow V, Wu S, Aguilar A, Bonner R Jr, Suarez E, De Luca F (2011) Association between oxidative stress and masked hypertension in a multi-ethnic population of obese children and adolescents. J Pediatr 158:628–633PubMedCrossRef
17.
go back to reference Túri S, Friedman A, Bereczki C, Papp F, Kovàcs J, Karg E, Németh I (2003) Oxidative stress in juvenile essential hypertension. J Hypertens 21:145–152PubMedCrossRef Túri S, Friedman A, Bereczki C, Papp F, Kovàcs J, Karg E, Németh I (2003) Oxidative stress in juvenile essential hypertension. J Hypertens 21:145–152PubMedCrossRef
18.
go back to reference Sladowska-Kozłowska J, Litwin M, Niemirska A, Płudowski P, Wierzbicka A, Skorupa E, Wawer ZT, Janas R (2012) Oxidative stress in hypertensive children before and after 1 year of antihypertensive therapy. Pediatr Nephrol 27:1943–1951PubMedPubMedCentralCrossRef Sladowska-Kozłowska J, Litwin M, Niemirska A, Płudowski P, Wierzbicka A, Skorupa E, Wawer ZT, Janas R (2012) Oxidative stress in hypertensive children before and after 1 year of antihypertensive therapy. Pediatr Nephrol 27:1943–1951PubMedPubMedCentralCrossRef
19.
go back to reference Litwin M, Niemirska Ś-KJ, Wierzbicka A, Janas R, Wawer ZT, Wisniewski A, Feber J (2010) Regression of target organ damage in children and adolescents with primary hypertension. Pediatr Nephrol 25:2489–2499PubMedPubMedCentralCrossRef Litwin M, Niemirska Ś-KJ, Wierzbicka A, Janas R, Wawer ZT, Wisniewski A, Feber J (2010) Regression of target organ damage in children and adolescents with primary hypertension. Pediatr Nephrol 25:2489–2499PubMedPubMedCentralCrossRef
20.
go back to reference Lever AF, Harrap SB (1992) Essential hypertension: a disorder of growth with origins in childhood? J Hypertens 10:101–120PubMedCrossRef Lever AF, Harrap SB (1992) Essential hypertension: a disorder of growth with origins in childhood? J Hypertens 10:101–120PubMedCrossRef
21.
go back to reference Katz SH, Hediger ML, Schall JI, Bowers IJ, Barker WF, Aurand S, Eveleth PB, Gruskin AB, Parks JS (1980) Blood pressure, growth and maturation from childhood through adolescence: mixed longitudinal analyses from Philadelphia Blood Pressure Project. Hypertension 2:55–69PubMedCrossRef Katz SH, Hediger ML, Schall JI, Bowers IJ, Barker WF, Aurand S, Eveleth PB, Gruskin AB, Parks JS (1980) Blood pressure, growth and maturation from childhood through adolescence: mixed longitudinal analyses from Philadelphia Blood Pressure Project. Hypertension 2:55–69PubMedCrossRef
22.
go back to reference Cho SD, Mueller W, Meininger JC, Liehr P, Chan W (2001) Blood pressure and sexual maturity In adolescents: the Heartfelt Study. Am J Hum Biol 13:227–234PubMedCrossRef Cho SD, Mueller W, Meininger JC, Liehr P, Chan W (2001) Blood pressure and sexual maturity In adolescents: the Heartfelt Study. Am J Hum Biol 13:227–234PubMedCrossRef
23.
go back to reference Pludowski P, Litwin M, Niemirska A, Jaworski M, Sladowska J, Kryskiewicz E, Karczmarewicz E, Neuhoff-Murawska J, Wierzbicka A, Lorenc RS (2009) Accelerated skeletal maturation in children with primary hypertension. Hypertension 54:1234–1239PubMedCrossRef Pludowski P, Litwin M, Niemirska A, Jaworski M, Sladowska J, Kryskiewicz E, Karczmarewicz E, Neuhoff-Murawska J, Wierzbicka A, Lorenc RS (2009) Accelerated skeletal maturation in children with primary hypertension. Hypertension 54:1234–1239PubMedCrossRef
24.
go back to reference Sun SS, Schubert CM (2009) Prolonged juvenile states and delay of cardiovascular and metabolic risk factors: The Fels Longitudinal Study. J Pediatr 155(suppl 7):e1–e6CrossRef Sun SS, Schubert CM (2009) Prolonged juvenile states and delay of cardiovascular and metabolic risk factors: The Fels Longitudinal Study. J Pediatr 155(suppl 7):e1–e6CrossRef
25.
go back to reference Halldorsson T, Gunnarsdottir I, Birgisdottir BE, Gudnason V, Aspelund T, Thorsdottir I (2010) Childhood growth and adult hypertension in a population of high birth weight. Hypertension 58:8–15CrossRef Halldorsson T, Gunnarsdottir I, Birgisdottir BE, Gudnason V, Aspelund T, Thorsdottir I (2010) Childhood growth and adult hypertension in a population of high birth weight. Hypertension 58:8–15CrossRef
26.
go back to reference Kivimaki M (2008) Association of age at menarche with cardiovascular risk factors, vascular structure, and function in adulthood: The Cardiovascular Risk in Young Finns Study. Am J Clin Nutr 87:1876–1882PubMed Kivimaki M (2008) Association of age at menarche with cardiovascular risk factors, vascular structure, and function in adulthood: The Cardiovascular Risk in Young Finns Study. Am J Clin Nutr 87:1876–1882PubMed
27.
go back to reference Okuda T, Grollman (1967) Passive transfer of autoimmune induced hypertension in the rat by lymph node cells. Tex Rep Biol Med 25:257–264PubMed Okuda T, Grollman (1967) Passive transfer of autoimmune induced hypertension in the rat by lymph node cells. Tex Rep Biol Med 25:257–264PubMed
28.
go back to reference Svendsen UG (1975) Studies elucidating the importance of thymus on the degree of increased blood pressure and vascular disease in renal hypertensive mice. A comparison of the disease in nude and haired littermates. Acta Pathol Microbiol Scand A 83:568–572PubMed Svendsen UG (1975) Studies elucidating the importance of thymus on the degree of increased blood pressure and vascular disease in renal hypertensive mice. A comparison of the disease in nude and haired littermates. Acta Pathol Microbiol Scand A 83:568–572PubMed
29.
go back to reference Svendsen UG (1976) The role of thymus for the development and prognosis of hypertension and hypertensive vascular disease in mice following renal infarction. Acta Pathol Microbiol Scand A 84:235–243PubMed Svendsen UG (1976) The role of thymus for the development and prognosis of hypertension and hypertensive vascular disease in mice following renal infarction. Acta Pathol Microbiol Scand A 84:235–243PubMed
30.
go back to reference Svendsen UG (1977) Spontaneous hypertension and hypertensive vascular disease in the NZB strain of mice. Acta Pathol Microbiol Scand A 85:548–554PubMed Svendsen UG (1977) Spontaneous hypertension and hypertensive vascular disease in the NZB strain of mice. Acta Pathol Microbiol Scand A 85:548–554PubMed
31.
go back to reference Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG (2007) Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204:2449–2460PubMedPubMedCentralCrossRef Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG (2007) Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204:2449–2460PubMedPubMedCentralCrossRef
32.
go back to reference Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, Paradis P, Schiffrin EL (2011) T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 57:469–476PubMedCrossRef Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, Paradis P, Schiffrin EL (2011) T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 57:469–476PubMedCrossRef
33.
go back to reference Chae CU, Lee RT, Rifai N, Ridker PM (2001) Blood pressure and inflammation in apparently healthy man. Hypertension 38:399–403PubMedCrossRef Chae CU, Lee RT, Rifai N, Ridker PM (2001) Blood pressure and inflammation in apparently healthy man. Hypertension 38:399–403PubMedCrossRef
34.
go back to reference Festa A, Jr A, Howard G, Mykkänen L, Tracy RP, Haffner SM (2000) Chronic subclinical inflammation as a part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42–47PubMedCrossRef Festa A, Jr A, Howard G, Mykkänen L, Tracy RP, Haffner SM (2000) Chronic subclinical inflammation as a part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42–47PubMedCrossRef
35.
go back to reference Lande MB, Pearson TA, Vermilion RP, Auinger P, Fernandez ID (2008) Elevated blood pressure, race/ethnicity, and C-reactive protein levels in children and adolescents. Pediatrics 122:1252–1257PubMedPubMedCentralCrossRef Lande MB, Pearson TA, Vermilion RP, Auinger P, Fernandez ID (2008) Elevated blood pressure, race/ethnicity, and C-reactive protein levels in children and adolescents. Pediatrics 122:1252–1257PubMedPubMedCentralCrossRef
36.
go back to reference Litwin M, Michalkiewicz J, Niemirska A, Gackowska L, Kubiszewska I, Wierzbicka A, Wawer ZT, Janas R (2010) Inflammatory activation in children with primary hypertension. Pediatr Nephrol 25:2489–2499PubMedPubMedCentralCrossRef Litwin M, Michalkiewicz J, Niemirska A, Gackowska L, Kubiszewska I, Wierzbicka A, Wawer ZT, Janas R (2010) Inflammatory activation in children with primary hypertension. Pediatr Nephrol 25:2489–2499PubMedPubMedCentralCrossRef
37.
go back to reference Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R (2007) Human T and natural killer cells possess a functional renin–angiotensin system: further mechanisms of angiotensin-induced inflammation. J Am Soc Nephrol 18:1093–1102PubMedCrossRef Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R (2007) Human T and natural killer cells possess a functional renin–angiotensin system: further mechanisms of angiotensin-induced inflammation. J Am Soc Nephrol 18:1093–1102PubMedCrossRef
38.
go back to reference Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, Weyand C, Harrison DG (2009) Regulation of T cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol 296:208–216CrossRef Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, Weyand C, Harrison DG (2009) Regulation of T cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol 296:208–216CrossRef
39.
go back to reference Benicky J, Sanchez-Lemus E, Pavel J, Saavedra JM (2009) Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Moll Neurobiol 29:781–792CrossRef Benicky J, Sanchez-Lemus E, Pavel J, Saavedra JM (2009) Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Moll Neurobiol 29:781–792CrossRef
40.
go back to reference Chon H, Gaillard CAJM, van der Meijden BB, Dijstelbloem HM, Kraaijenhagen RJ, van Leenen D, Holstege FC, Joles JA, Bluyssen HA, Koomans HA, Braam B (2004) Broadly altered gene expression in blood leukocytes in essential hypertension is absent during treatment. Hypertension 43:947–951PubMedCrossRef Chon H, Gaillard CAJM, van der Meijden BB, Dijstelbloem HM, Kraaijenhagen RJ, van Leenen D, Holstege FC, Joles JA, Bluyssen HA, Koomans HA, Braam B (2004) Broadly altered gene expression in blood leukocytes in essential hypertension is absent during treatment. Hypertension 43:947–951PubMedCrossRef
41.
go back to reference Coppo M, Bandinelli M, Berni A, Galastri S, Abbate R, Poggesi L, Marra F, Gensini GF, Boddi M (2011) Ang-II upregulation of T lymphocyte renin–angiotensin system is amplified by low-grade inflammation in human hypertension. Am J Hypertens 24:716–723PubMedCrossRef Coppo M, Bandinelli M, Berni A, Galastri S, Abbate R, Poggesi L, Marra F, Gensini GF, Boddi M (2011) Ang-II upregulation of T lymphocyte renin–angiotensin system is amplified by low-grade inflammation in human hypertension. Am J Hypertens 24:716–723PubMedCrossRef
42.
go back to reference Litwin M, Michałkiewicz TJ, Niemirska A, Wierzbicka A, Szalecki M (2013) Altered genes profile of renin–angiotensin system, immune system, and adipokines receptors in leukocytes of children with primary hypertension. Hypertension 61:431–436PubMedCrossRef Litwin M, Michałkiewicz TJ, Niemirska A, Wierzbicka A, Szalecki M (2013) Altered genes profile of renin–angiotensin system, immune system, and adipokines receptors in leukocytes of children with primary hypertension. Hypertension 61:431–436PubMedCrossRef
43.
go back to reference Bierhaus A, Humpert PM, Nawroth PP (2004) NF-kappaB as a molecular link between psychosocial stress and organ dysfunction. Pediatr Nephrol 19:1189–1191PubMedCrossRef Bierhaus A, Humpert PM, Nawroth PP (2004) NF-kappaB as a molecular link between psychosocial stress and organ dysfunction. Pediatr Nephrol 19:1189–1191PubMedCrossRef
44.
go back to reference Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D, Ferstl R, von Eynatten M, Wendt T, Rudofsky G, Joswig M, Morcos M, Schwaninger M, McEwen B, Kirschbaum C, Nawroth PP (2003) A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A 100:1920–1925PubMedPubMedCentralCrossRef Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D, Ferstl R, von Eynatten M, Wendt T, Rudofsky G, Joswig M, Morcos M, Schwaninger M, McEwen B, Kirschbaum C, Nawroth PP (2003) A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A 100:1920–1925PubMedPubMedCentralCrossRef
45.
go back to reference Youn J-C, Yu HT, Lim BJ, Koh MJ, Lee J, Chang D-Y, Choi YS, Lee S-H, Kang S-M, Jang Y, Yoo OJ, Shin E-C, Park S (2013) Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension 62:126–133PubMedCrossRef Youn J-C, Yu HT, Lim BJ, Koh MJ, Lee J, Chang D-Y, Choi YS, Lee S-H, Kang S-M, Jang Y, Yoo OJ, Shin E-C, Park S (2013) Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension 62:126–133PubMedCrossRef
46.
go back to reference Feber J, Ruzicka M, Geier P, Litwin M (2014) Autonomic nervous system dysregulation in pediatric hypertension. Curr Hypertens Rep 16:426PubMedCrossRef Feber J, Ruzicka M, Geier P, Litwin M (2014) Autonomic nervous system dysregulation in pediatric hypertension. Curr Hypertens Rep 16:426PubMedCrossRef
47.
go back to reference Niemirska A, Obrycki Ł, Wojciechowska E, Litwin M (2014) Hemodynamics of primary hypertension in children. Pediatr Nephrol 29:1724 (abstract) Niemirska A, Obrycki Ł, Wojciechowska E, Litwin M (2014) Hemodynamics of primary hypertension in children. Pediatr Nephrol 29:1724 (abstract)
48.
go back to reference Julius S, Valentini M, Palatini P (2000) Overweight and Hypertension: a two-way street? Hypertension 35:807–813PubMedCrossRef Julius S, Valentini M, Palatini P (2000) Overweight and Hypertension: a two-way street? Hypertension 35:807–813PubMedCrossRef
49.
go back to reference Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS, Astruc B, Mayer JP, Brage S, See TC, Lomas DJ, O’Rahilly S, Farooqi IS (2009) Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 360:44–52PubMedCrossRef Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS, Astruc B, Mayer JP, Brage S, See TC, Lomas DJ, O’Rahilly S, Farooqi IS (2009) Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 360:44–52PubMedCrossRef
50.
go back to reference Syme C, Abrahamowicz M, Leonard GT, Perron M, Pitiot A, Qiu X, Richer L, Totman J, Veillette S, Xiao Y, Gaudet D, Paus T, Pausova Z (2008) Intra-abdominal adiposity and individual components of the metabolic syndrome in adolescence: sex differences and underlying mechanisms. Arch Pediatr Adolesc Med 162:453–461PubMedCrossRef Syme C, Abrahamowicz M, Leonard GT, Perron M, Pitiot A, Qiu X, Richer L, Totman J, Veillette S, Xiao Y, Gaudet D, Paus T, Pausova Z (2008) Intra-abdominal adiposity and individual components of the metabolic syndrome in adolescence: sex differences and underlying mechanisms. Arch Pediatr Adolesc Med 162:453–461PubMedCrossRef
51.
go back to reference Kułaga Z, Litwin M, Grajda A, Kułaga K, Gurzkowska B, Góźdź M, Pan H; OLAF Study Group (2012) Oscillometric blood pressure percentiles for Polish normal weight school-aged children and adolescents. J Hypertens 30:1942–1954CrossRef Kułaga Z, Litwin M, Grajda A, Kułaga K, Gurzkowska B, Góźdź M, Pan H; OLAF Study Group (2012) Oscillometric blood pressure percentiles for Polish normal weight school-aged children and adolescents. J Hypertens 30:1942–1954CrossRef
52.
go back to reference Litwin M, Simonetti GD, Niemirska A, Ruzicka M, Wühl E, Schaefer F, Feber J (2010) Altered cardiovascular rhythmicity in children with white coat and ambulatory hypertension. Pediatr Res 67:419–423PubMedCrossRef Litwin M, Simonetti GD, Niemirska A, Ruzicka M, Wühl E, Schaefer F, Feber J (2010) Altered cardiovascular rhythmicity in children with white coat and ambulatory hypertension. Pediatr Res 67:419–423PubMedCrossRef
53.
go back to reference Niemirska A, Litwin M, Feber J, Jurkiewicz E (2013) Blood pressure rhythmicity and visceral Fat in children with hypertension. Hypertension 62:782–788PubMedCrossRef Niemirska A, Litwin M, Feber J, Jurkiewicz E (2013) Blood pressure rhythmicity and visceral Fat in children with hypertension. Hypertension 62:782–788PubMedCrossRef
54.
go back to reference Stabouli S, Kotsis V, Rizos Z, Toumanidis S, Karagianni C, Constantopoulos A, Zakopoulos N (2009) Left ventricular mass in normotensive, pre-hypertensive and hypertensive children and adolescents. Pediatr Nephrol 24:1545–1551PubMedCrossRef Stabouli S, Kotsis V, Rizos Z, Toumanidis S, Karagianni C, Constantopoulos A, Zakopoulos N (2009) Left ventricular mass in normotensive, pre-hypertensive and hypertensive children and adolescents. Pediatr Nephrol 24:1545–1551PubMedCrossRef
55.
go back to reference Kollias A, Dafni M, Poulidakis E, Ntineri A, Stergiou GS (2014) Out of office blood pressure and target organ damage in children and adolescents: a systematic review and meta-analysis. J Hypertens 32:2315–2331PubMedCrossRef Kollias A, Dafni M, Poulidakis E, Ntineri A, Stergiou GS (2014) Out of office blood pressure and target organ damage in children and adolescents: a systematic review and meta-analysis. J Hypertens 32:2315–2331PubMedCrossRef
56.
go back to reference Litwin M, Niemirska A, Ruzicka M, Feber J (2009) White coat hypertension in children: not rare and not benign? J Am Soc Hypertens 3:416–423PubMedCrossRef Litwin M, Niemirska A, Ruzicka M, Feber J (2009) White coat hypertension in children: not rare and not benign? J Am Soc Hypertens 3:416–423PubMedCrossRef
57.
go back to reference Sorof JM, Cardwell G, Franco K, Portman RJ (2002) Ambulatory blood pressure and left ventricular mass in hypertensive children. Hypertension 39:903–908PubMedCrossRef Sorof JM, Cardwell G, Franco K, Portman RJ (2002) Ambulatory blood pressure and left ventricular mass in hypertensive children. Hypertension 39:903–908PubMedCrossRef
58.
go back to reference Ltwin M, Niemirska A, Sladowska J, Antoniewicz J, Daszkowska J, Wierzbicka A, Wawer ZT, Grenda R (2006) Left ventricular hypertrophy and arterial wall thickening in children with essential hypertension. Pediatr Nephrol 21:811–819CrossRef Ltwin M, Niemirska A, Sladowska J, Antoniewicz J, Daszkowska J, Wierzbicka A, Wawer ZT, Grenda R (2006) Left ventricular hypertrophy and arterial wall thickening in children with essential hypertension. Pediatr Nephrol 21:811–819CrossRef
59.
go back to reference Brady TM, Fivush B, Flynn JT, Parekh R (2008) Ability of blood pressure to predict left ventricular hypertrophy in children with primary hypertension. J Pediatr 152:73–78PubMedCrossRef Brady TM, Fivush B, Flynn JT, Parekh R (2008) Ability of blood pressure to predict left ventricular hypertrophy in children with primary hypertension. J Pediatr 152:73–78PubMedCrossRef
60.
go back to reference Gerhard-Herman M, Smoot LB, Wake N, Kieran MW, Kleinman ME, Miller DT, Schwartzman A, Giobbie-Hurder A, Neuberg D, Gordon LB (2012) Mechanisms of premature vascular aging in children with Hutchinson–Gilford progeria syndrome. Hypertension 59:92–97PubMedPubMedCentralCrossRef Gerhard-Herman M, Smoot LB, Wake N, Kieran MW, Kleinman ME, Miller DT, Schwartzman A, Giobbie-Hurder A, Neuberg D, Gordon LB (2012) Mechanisms of premature vascular aging in children with Hutchinson–Gilford progeria syndrome. Hypertension 59:92–97PubMedPubMedCentralCrossRef
61.
go back to reference Kotsis V, Stabouli S, Karafillis I, Nilsson P (2011) Early vascular aging and the role of central blood pressure. J Hypertens 29:1847–1853PubMedCrossRef Kotsis V, Stabouli S, Karafillis I, Nilsson P (2011) Early vascular aging and the role of central blood pressure. J Hypertens 29:1847–1853PubMedCrossRef
62.
go back to reference Ferreira I, van de Laar RJ, Prins MH, Twisk JW, Stehouwer CD (2012) Carotid stiffness in young adults: a life-course analysis of its early determinants: the Amsterdam Growth and Health Study. Hypertension 59:54–61PubMedCrossRef Ferreira I, van de Laar RJ, Prins MH, Twisk JW, Stehouwer CD (2012) Carotid stiffness in young adults: a life-course analysis of its early determinants: the Amsterdam Growth and Health Study. Hypertension 59:54–61PubMedCrossRef
63.
go back to reference Harrison DG1, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM (2011) Inflammation, immunity, and hypertension. Hypertension 57:132–140PubMedPubMedCentralCrossRef Harrison DG1, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM (2011) Inflammation, immunity, and hypertension. Hypertension 57:132–140PubMedPubMedCentralCrossRef
65.
go back to reference Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ (2004) Oxidative Stress, Renal infiltration of immune cells and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 286:606–616CrossRef Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ (2004) Oxidative Stress, Renal infiltration of immune cells and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 286:606–616CrossRef
66.
go back to reference Parra G, Quiroz Y, Salazar J, Bravo Y, Pons H, Chavez M, Rj J, Rodriguez-Iturbe B (2008) Experimental induction of salt-sensitive hypertension is associated with lymphocyte proliferative response to HSP70. Kidney Int 74:S55–S59CrossRef Parra G, Quiroz Y, Salazar J, Bravo Y, Pons H, Chavez M, Rj J, Rodriguez-Iturbe B (2008) Experimental induction of salt-sensitive hypertension is associated with lymphocyte proliferative response to HSP70. Kidney Int 74:S55–S59CrossRef
67.
go back to reference Pons H, Ferrebuz A, Quiroz Y, Romero-Vasquez F, Parra G, Johnson RJ, Rodriguez-Iturbe B (2013) Immune reactivity to heat shock protein 70 expressed in the kidney is cause of salt sensitive hypertension. Am J Physiol Renal Physiol 304:289–299CrossRef Pons H, Ferrebuz A, Quiroz Y, Romero-Vasquez F, Parra G, Johnson RJ, Rodriguez-Iturbe B (2013) Immune reactivity to heat shock protein 70 expressed in the kidney is cause of salt sensitive hypertension. Am J Physiol Renal Physiol 304:289–299CrossRef
68.
go back to reference Frostegard J, Lemne C, Andersson B, van der Zee R, Kiessling R, deFaire U (1997) Association of serum antibodies to heat-shock protein 65 with borderline hypertension. Hypertension 29:40–44PubMedCrossRef Frostegard J, Lemne C, Andersson B, van der Zee R, Kiessling R, deFaire U (1997) Association of serum antibodies to heat-shock protein 65 with borderline hypertension. Hypertension 29:40–44PubMedCrossRef
69.
go back to reference Pockley AG, Wu R, Lemne C, Kiessling R, de Faire U, Frostegard J (2000) Circulating heat shock protein 60 is associated with early cardiovascular Disease. Hypertension 36:303–307PubMedCrossRef Pockley AG, Wu R, Lemne C, Kiessling R, de Faire U, Frostegard J (2000) Circulating heat shock protein 60 is associated with early cardiovascular Disease. Hypertension 36:303–307PubMedCrossRef
70.
go back to reference Knoflach M, Bernhard D, Wick G (2005) Anti-HSP60 immunity is already associated with atherosclerosis early in life. Ann N Y Acad Sci 1051:323–331PubMedCrossRef Knoflach M, Bernhard D, Wick G (2005) Anti-HSP60 immunity is already associated with atherosclerosis early in life. Ann N Y Acad Sci 1051:323–331PubMedCrossRef
71.
go back to reference Knoflach M, Kiechl S, Mayrl B, Kind M, Gaston JS, van der Zee R, Faggionato A, Mayr A, Willeit J, Wick G (2007) T-cell reactivity against HSP60 relates to early but not advanced atherosclerosis. Atherosclerosis 195:333–338PubMedCrossRef Knoflach M, Kiechl S, Mayrl B, Kind M, Gaston JS, van der Zee R, Faggionato A, Mayr A, Willeit J, Wick G (2007) T-cell reactivity against HSP60 relates to early but not advanced atherosclerosis. Atherosclerosis 195:333–338PubMedCrossRef
72.
go back to reference Bravo Y, Quiroz Y, Ferrebuz A, Vaziri ND, Rodríguez-Iturbe B (2007) Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension. Am J Physiol Renal Physiol 293:616–623CrossRef Bravo Y, Quiroz Y, Ferrebuz A, Vaziri ND, Rodríguez-Iturbe B (2007) Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension. Am J Physiol Renal Physiol 293:616–623CrossRef
73.
go back to reference Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B (2006) Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol 17:218–225CrossRef Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B (2006) Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol 17:218–225CrossRef
74.
go back to reference Baradaran A, Nasri H, Rafieian-Kopaei M (2014) Oxidative stress and hypertension: Possibility of hypertension therapy with antioxidants. J Res Med 19:358–367 Baradaran A, Nasri H, Rafieian-Kopaei M (2014) Oxidative stress and hypertension: Possibility of hypertension therapy with antioxidants. J Res Med 19:358–367
75.
go back to reference Roque FR, Hernanz R, Salaices M, Briones AM (2013) Exercise training and cardiometabolic diseases: focus on the vascular system. Curr Hypertens Rep 15:204–214PubMedCrossRef Roque FR, Hernanz R, Salaices M, Briones AM (2013) Exercise training and cardiometabolic diseases: focus on the vascular system. Curr Hypertens Rep 15:204–214PubMedCrossRef
76.
go back to reference Kokkinos P (2014) Cardiorespiratory fitness, exercise, and blood pressure. Hypertension 64:1160–1164PubMedCrossRef Kokkinos P (2014) Cardiorespiratory fitness, exercise, and blood pressure. Hypertension 64:1160–1164PubMedCrossRef
77.
go back to reference Liu J, Sui X, Lavie CJ, Zhou H, Park YM, Cai B, Liu J, Blair SN (2014) Effects of cardiorespiratory fitness on blood pressure trajectory with aging in a cohort of healthy men. J Am Coll Cardiol 64:1245–1253PubMedPubMedCentralCrossRef Liu J, Sui X, Lavie CJ, Zhou H, Park YM, Cai B, Liu J, Blair SN (2014) Effects of cardiorespiratory fitness on blood pressure trajectory with aging in a cohort of healthy men. J Am Coll Cardiol 64:1245–1253PubMedPubMedCentralCrossRef
78.
go back to reference Leary SD, Ness AR, Smith GD, Cs M, Deere K, Blair SN, Riddoch C (2008) Physical activity and blood pressure in childhood: findings from a population based study. Hypertension 82:16–23 Leary SD, Ness AR, Smith GD, Cs M, Deere K, Blair SN, Riddoch C (2008) Physical activity and blood pressure in childhood: findings from a population based study. Hypertension 82:16–23
79.
go back to reference Rocchini AP, Katch V, Anderson J, Hinderliter J, Becque J, Martin M, Marks C (1988) Blood pressure in obese adolescents: effect of weight loss. Pediatrics 82:16–23PubMed Rocchini AP, Katch V, Anderson J, Hinderliter J, Becque J, Martin M, Marks C (1988) Blood pressure in obese adolescents: effect of weight loss. Pediatrics 82:16–23PubMed
80.
go back to reference Woo KS, Chook P, Yu CW, Sung RY, Qiao M, Leung SS, Lam CW, Metreweli C, Celermajer DS (2004) Effects of diet and exercise on obesity-related vascular dysfunction in children. Circulation 109:1981–1986PubMedCrossRef Woo KS, Chook P, Yu CW, Sung RY, Qiao M, Leung SS, Lam CW, Metreweli C, Celermajer DS (2004) Effects of diet and exercise on obesity-related vascular dysfunction in children. Circulation 109:1981–1986PubMedCrossRef
81.
go back to reference Messerli FH, Bangalore S, Julius S (2008) Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 117:2706–2715PubMedCrossRef Messerli FH, Bangalore S, Julius S (2008) Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 117:2706–2715PubMedCrossRef
82.
go back to reference Elliott WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369:201–207PubMedCrossRef Elliott WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369:201–207PubMedCrossRef
83.
go back to reference Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J; ALLHAT Collaborative Research Group (2006) Fasting glucose levels and incident diabetes mellitus in older non-diabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 166:2191–2201CrossRef Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J; ALLHAT Collaborative Research Group (2006) Fasting glucose levels and incident diabetes mellitus in older non-diabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 166:2191–2201CrossRef
85.
go back to reference Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC (2001) Hypothesis: Beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 37:250–254PubMedCrossRef Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC (2001) Hypothesis: Beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 37:250–254PubMedCrossRef
86.
go back to reference Bangalore S, Parkar S, Grossman E, Messerli FH (2007) A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 100:1254–1262PubMedCrossRef Bangalore S, Parkar S, Grossman E, Messerli FH (2007) A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 100:1254–1262PubMedCrossRef
87.
go back to reference Falkner B, Francos G, Kushner H (2006) Metoprolol succinate, a selective b-adrenergic blocker, has no effect on insulin sensitivity. J Clin Hypertens (Greenwich) 8:336–343CrossRef Falkner B, Francos G, Kushner H (2006) Metoprolol succinate, a selective b-adrenergic blocker, has no effect on insulin sensitivity. J Clin Hypertens (Greenwich) 8:336–343CrossRef
88.
go back to reference Falkner B, Kushner H (2008) Treatment with metoprolol succinate, a selective beta adrenergic blocker, lowers blood pressure without altering insulin sensitivity in diabetic patients. J Clin Hypertens (Greenwich) 10:51–57CrossRef Falkner B, Kushner H (2008) Treatment with metoprolol succinate, a selective beta adrenergic blocker, lowers blood pressure without altering insulin sensitivity in diabetic patients. J Clin Hypertens (Greenwich) 10:51–57CrossRef
89.
go back to reference Agabiti Rosei E, Rizzoni D (2007) Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 67:1097–1107PubMedCrossRef Agabiti Rosei E, Rizzoni D (2007) Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 67:1097–1107PubMedCrossRef
90.
go back to reference Ayers K, Byrne LM, DeMatteo A, Brown NJ (2012) Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension 59:893–898PubMedPubMedCentralCrossRef Ayers K, Byrne LM, DeMatteo A, Brown NJ (2012) Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension 59:893–898PubMedPubMedCentralCrossRef
91.
go back to reference Noto H, Goto A, Tsjimoto T, Noda M (2013) Effect of calcium channel blockers on incidence of diabetes: a meta-analysis. Diabetes Metab Syndr Obes 6:257–261PubMedPubMedCentralCrossRef Noto H, Goto A, Tsjimoto T, Noda M (2013) Effect of calcium channel blockers on incidence of diabetes: a meta-analysis. Diabetes Metab Syndr Obes 6:257–261PubMedPubMedCentralCrossRef
92.
go back to reference Shen L, Shah BR, Reyes EM, Thomas L, Wojdyla D, Diem P, Leiter LA, Charbonnel B, Mareev V, Horton ES, Haffner SM, Soska V, Holman R, Bethel MA, Schaper F, Sun JL, McMurray JJ, Califf RM, Krum H (2013) Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ 347:f6745PubMedPubMedCentralCrossRef Shen L, Shah BR, Reyes EM, Thomas L, Wojdyla D, Diem P, Leiter LA, Charbonnel B, Mareev V, Horton ES, Haffner SM, Soska V, Holman R, Bethel MA, Schaper F, Sun JL, McMurray JJ, Califf RM, Krum H (2013) Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ 347:f6745PubMedPubMedCentralCrossRef
93.
go back to reference Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145–153PubMedCrossRef Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145–153PubMedCrossRef
94.
go back to reference Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359:995–1003PubMedCrossRef Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359:995–1003PubMedCrossRef
95.
go back to reference Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg BE, Wester PO, Björck JE (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 353:611–616PubMedCrossRef Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg BE, Wester PO, Björck JE (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 353:611–616PubMedCrossRef
96.
go back to reference Abuissa H, Jones PG, Marso SP, O’Keefe JH (2005) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 46:821–826PubMedCrossRef Abuissa H, Jones PG, Marso SP, O’Keefe JH (2005) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 46:821–826PubMedCrossRef
97.
go back to reference Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM (2005) Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45:356–362PubMedCrossRef Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM (2005) Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45:356–362PubMedCrossRef
98.
go back to reference Dharma AM (2002) Adipose tissue: a mediator of cardiovascular risk. Int J Obes Relat Metab Disord 4:5–7 Dharma AM (2002) Adipose tissue: a mediator of cardiovascular risk. Int J Obes Relat Metab Disord 4:5–7
99.
go back to reference Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM (2002) Hormonal regulation of the human adipose-tissue renin–angiotensin system: relationship to obesity and hypertension. J Hypertens 20:965–973PubMedCrossRef Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM (2002) Hormonal regulation of the human adipose-tissue renin–angiotensin system: relationship to obesity and hypertension. J Hypertens 20:965–973PubMedCrossRef
100.
go back to reference Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43:993–1002PubMedCrossRef Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43:993–1002PubMedCrossRef
101.
go back to reference Shimabukuro M, Tanaka H, Shimabukuro T (2007) Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 25:841–848PubMedCrossRef Shimabukuro M, Tanaka H, Shimabukuro T (2007) Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 25:841–848PubMedCrossRef
102.
go back to reference Michalkiewicz J, Barth C, Chrzanowska K, Gregorek H, Syczewska M, Weemeas CMB, Madaliński K, Dzierżanowska D, Stachowski J (2003) Abnormalities in the T and NK lymphocyte phenotype in patients with Nijmegen breakage syndrome. Clin Exp Immunol 134:482–490PubMedPubMedCentralCrossRef Michalkiewicz J, Barth C, Chrzanowska K, Gregorek H, Syczewska M, Weemeas CMB, Madaliński K, Dzierżanowska D, Stachowski J (2003) Abnormalities in the T and NK lymphocyte phenotype in patients with Nijmegen breakage syndrome. Clin Exp Immunol 134:482–490PubMedPubMedCentralCrossRef
Metadata
Title
Primary hypertension is a disease of premature vascular aging associated with neuro-immuno-metabolic abnormalities
Authors
Mieczysław Litwin
Janusz Feber
Anna Niemirska
Jacek Michałkiewicz
Publication date
01-02-2016
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 2/2016
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-015-3065-y

Other articles of this Issue 2/2016

Pediatric Nephrology 2/2016 Go to the issue